1. Home
  2. Live Updates
  3. Johnson zytiga

Live Breaking News & Updates on Johnson zytiga

Stay informed with the latest breaking news from Johnson zytiga on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Johnson zytiga and stay connected to the pulse of your community

AstraZeneca's Lynparza to remain dominant in PARP inhibitors market

Back in 2014, AstraZeneca and Merck were the first to receive FDA approval for their PARP inhibitor Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients.

Johnson-zytiga , Biswajit-podder , Astrazeneca , Markets-amp-regulations , Ipelines , Merging-markets , Strazeneca , Arp-inhibitor , Ncology , Linical-trials ,

Novartis pays $150M for Arvinas' prostate tumor protein degrader

Novartis pays $150M for Arvinas' prostate tumor protein degrader
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Johnson-zytiga , John-houston , Novartis ,

Eli Lilly's Verzenio fails prostate cancer test as possible Novartis showdown nears

Eli Lilly's Verzenio fails prostate cancer test as possible Novartis showdown nears
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Switzerland , Swiss , Novarti-kisqali , Eli-lilly-verzenio , Johnson-zytiga , Dan-skovronsky , Novartis , Eli-lilly ,

Closing ASCO: AstraZeneca's 'very special' meeting, more CAR-T survival data and Pfizer's PARP play

BioPharma

Australia , United-states , United-kingdom , British , American , Warner-biddle , Jonathan-gardner , Pascal-soriot , Johnson-zytiga , Suneet-varma , Bristol-myers-squibb , Ned-pagliarulo

AZ, Merck's Lynparza wins FDA nod in prostate cancer subgroup following advisory committee vote

After a panel of independent experts endorsed a narrow approval for AstraZeneca and Merck’s Lynparza in metastatic castration-resistant prostate cancer…

Johnson-zytiga , Merck-lynparza , Astrazeneca , News , Ggregator , Reaking-news , Uration , Edia ,

Pfizer makes case for PARP-blocking drug in prostate cancer

BioPharma

Johnson-zytiga , Pfizer , Astrazeneca , Drug-administration , Merck-co , European-union-okd , Dive-brief , Clovis-oncology , European-union , Pharma , Clinical-trials

Pfizer says PARP inhibitor succeeds in prostate cancer study

BioPharma

Johnson-zytiga , Pfizer , Astrazeneca , Drug-administration , Dive-brief , Pharma , Clinical-trials ,

Trial backs role for Lynparza in second-line prostate cancer

Trial backs role for Lynparza in second-line prostate cancer
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Jose-baselga , Glaxosmithkline-tesaro-zejula , Johnson-zytiga , Astrazeneca , Merck-co , Clovis-oncology ,